CDC has published an article on errors associated with administration of the new Shingrix vaccine in the Morbidity and Mortality Weekly Report on May 25, 2018. These errors were reported to the Vaccine Adverse Event Reporting System (VAERS) during the first four months of Shingrix monitoring.
There were 155 reports to the VAERS system, of which 13 (8%) documented vaccine administration errors. In addition, CDC has received calls about Shingrix administration errors or how to avoid them. The following errors/problems were described:
Please note that Shingrix administered through the appropriate IM route is associated with high rates of local and systemic reactions. However, erroneous SQ injection can increase the likelihood of these episodes.
We hope this information helpful.
If you have questions about Shingrix recommendations, please call the Immunization Program at 617-983-6800 and ask to speak to an immunization epidemiologist or nurse.
This report highlights your jurisdiction's HPV–associated cancer burden in addition to distribution data for all CDC and non-CDC distributed Gardasil 9 vaccines for 2017. The graph on the front page of the HPV Vaccination Report indicates your jurisdiction's progress towards a "Goal" of distributing enough HPV vaccine to immunize the estimated total number of 11-year-olds in your jurisdiction. The 2015 US Census and American Community Survey were used to obtain the population estimate of 11-year-olds in your jurisdiction. Based on this estimate, we were able to calculate the number of doses needed to immunize this cohort in your state or city with 2 doses of vaccine. Historically in the United States, 20% of annual HPV vaccine doses have been distributed in the first quarter, 20% in the second quarter, 35% in the third quarter, and 25% in the fourth quarter. These are the benchmarks we used to measure your jurisdiction's progress each quarter. The gold arrow indicates your jurisdiction's ordering trend last year and its progress towards distributing100% of its estimated HPV vaccine doses in 2017. Data presented in this report includes all CDC and non-CDC HPV vaccine orders. Although we're estimating the number of doses needed to vaccinate your 11-year-old cohort, doses that were distributed in 2017 may have been administered to individuals between the ages of 9 and 26 years.
Here is the December 2017 HPV vaccination report. The December report highlights HPV vaccination coverage estimates for your jurisdiction from the 2016 National Immunization Survey-Teen. More HPV-related material and resources can be found on our HPV Portal. For more information on HPV-associated cancers, visit here. If you have any questions, please contact firstname.lastname@example.org.
The Advisory Committee on Immunization Practices recommendations for the newly licensed recombinant zoster vaccine (RZV), Shingrix, by GlaxoSmithKline for the prevention were published in the MMWR on January 26, 2018. Shingrix is a 2-dose vaccine containing recombinant glycoprotein E and an adjuvant (AS01B). RZV is approved for use in those >50 years for the prevention of shingles and its complications. Initial clinical trials of RZV show higher vaccine efficacy across all age groups compared to zoster vaccine live (ZVL), Zostavax. Please see the attached recommendations for detailed clinical guidance
Shingrix can be given regardless of: 1) prior receipt of varicella vaccine; 2) prior receipt of ZVL; and 3) prior history of herpes zoster. Do not screen for a history of varicella (verbally or via laboratory serology).
Shingrix should be stored in the refrigerator at 2-8°C (not in the freezer). After reconstitution, it must be used within 6 hours or be discarded.
CDC has updated its shingles vaccination websites to reflect the new recommendations:
CDC has released the General Best Practice Guidelines for Immunization as an online report, and it is available on the Advisory Committee on Immunization Practices (ACIP) web page (HERE). The General Best Practice Guidelines for Immunization replace the General Recommendations on Immunization, last published in the Morbidity and Mortality Weekly Report (MMWR) in 2011.
The General Best Practice Guidelines for Immunization goes beyond vaccination recommendations to give providers guidelines on vaccination practice. The document will help vaccination providers to assess vaccine benefits and risks, use recommended administration practices, understand the most effective strategies for ensuring that vaccination coverage in the population remains high, and communicate the importance of vaccination to reduce the effects of vaccine-preventable disease.
By releasing the General Best Practice Guidelines for Immunization as an online report, ACIP will be able to update the document more quickly, giving vaccination providers the most up-to-date guidance on vaccination practice.
We encourage you to share General Best Practice Guidelines for Immunization with your partners and health care professionals. Attached is a sample announcement you can modify to post online or share through a newsletter, as well as sample tweets.
Continuing education (CE) credit is available for the General Best Practice Guidelines for Immunization.
To receive updates on this and other ACIP recommendations and guidelines, sign up at CLICK HERE.
If you have questions regarding immunization practice, please send them to NIPinfo@cdc.gov. As always, if you have questions about immunizations please call the MDPH Immunization Program at 617-983-6800 and ask to speak to an immunization epidemiologist.